

5 October 2022

Diaceutics PLC
("Diaceutics" or "the Company")

Purchase of Shares and PDMR Shareholding

[Diaceutics PLC](#), (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the precision medicine market, announces that on 4 October 2022, Deborah Davis, the Chair of Diaceutics, purchased 21,200 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 81 pence per Ordinary Share. As a result of the purchase, Deborah's shareholding is 86,000 Ordinary Shares, representing approximately 0.10% of the Company's issued share capital.

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)
Ben Maddison
Stewart Wallace
Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR
Caroline Forde
Kieran Breheny
Matthew Young

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Deborah Davis
2 Reason for notification		
a.	Position/Status	Chair
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Purchase				
c.	Price(s) and volume(s)	Share purchase: <table border="1" data-bbox="507 488 954 618"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>81 p</td> <td>21,200</td> </tr> </tbody> </table>	Price(s)	Volume(s)	81 p	21,200
Price(s)	Volume(s)					
81 p	21,200					
d.	Date of the transaction	4 October 2022				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFFFFLISLSIIF